Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Receivables - Net (2021 - 2025)

Historic Receivables - Net for Tg Therapeutics (TGTX) over the last 5 years, with Q3 2025 value amounting to $265.4 million.

  • Tg Therapeutics' Receivables - Net rose 12931.9% to $265.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.4 million, marking a year-over-year increase of 12931.9%. This contributed to the annual value of $129.2 million for FY2024, which is 15284.29% up from last year.
  • Per Tg Therapeutics' latest filing, its Receivables - Net stood at $265.4 million for Q3 2025, which was up 12931.9% from $231.5 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Receivables - Net peaked at $265.4 million during Q3 2025, and registered a low of $88000.0 during Q2 2022.
  • Moreover, its 5-year median value for Receivables - Net was $39.3 million (2023), whereas its average is $70.7 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first crashed by 9054.78% in 2022, then surged by 1976818.18% in 2023.
  • Tg Therapeutics' Receivables - Net (Quarter) stood at $1.4 million in 2021, then plummeted by 93.66% to $88000.0 in 2022, then soared by 57960.23% to $51.1 million in 2023, then soared by 152.84% to $129.2 million in 2024, then soared by 105.43% to $265.4 million in 2025.
  • Its last three reported values are $265.4 million in Q3 2025, $231.5 million for Q2 2025, and $190.1 million during Q1 2025.